If you would like to learn more or make an appointment, please call our team.
The Neurofibromatosis (NF) Center team is seeking neuroimaging biomarkers of the neurocognitive deficits that sometimes present in NF1. We hope to develop treatments that will improve cognitive outcomes for these patients. One possibility is MEK-inhibition medication, which has already proved effective at stopping the growth of some neurofibromas and gliomas in these patients. Data also suggest that cognitive improvement occurs with exercise for these patients.
We are using increasingly sophisticated analytic tools to study genotype-phenotype matching, which could help us to better predict disease severity as well as suggesting the specific types and locations of tumors to look for